Literature DB >> 8664410

Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer.

L Lipworth1, H O Adami, D Trichopoulos, K Carlström, C Mantzoros.   

Abstract

Serum concentrations of estrone, androstenedione, testosterone, and sex hormone-binding globulin (SHBG) were measured postoperatively in 122 postmenopausal women with incident breast cancer and 122 age-matched population controls. After mutual adjustment, through conditional logistic regression, between the hormonal variables and body mass index (BMI), the odds ratios for increasing control-defined quartiles of estrone and androstenedione, respectively, were 1.00, 1.44, 1.76, 1.94 and 1.00, 0.83, 0.97, 2.43; there was no association of testosterone with breast cancer risk. Moreover, the odds ratios for increasing quartiles of SHBG and BMI were 1.00, 0.72, 0.28, 0.25 and 1.00, 0.39, 0.28, 0.19, respectively. This study reveals sharp contrasts in breast cancer risk between women with high estrone and low BMI and SHBG, vs women with low estrone and high BMI and SHBG.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8664410     DOI: 10.1097/00001648-199601000-00017

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  11 in total

1.  Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women.

Authors:  Julie R Palmer; Nelsy Castro-Webb; Kimberly Bertrand; Traci N Bethea; Gerald V Denis
Journal:  Cancer Res       Date:  2017-11-15       Impact factor: 12.701

Review 2.  Sex hormone-binding globulin: not only a transport protein. What news is around the corner?

Authors:  N Fortunati
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

3.  Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.

Authors:  L Löfgren; B Wallberg; N Wilking; T Fornander; L E Rutqvist; K Carlström; B von Schoultz; E von Schoultz
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 4.  The prognostic outcome of 'type 2 diabetes mellitus and breast cancer' association pivots on hypoxia-hyperglycemia axis.

Authors:  Ilhaam Ayaz Durrani; Attya Bhatti; Peter John
Journal:  Cancer Cell Int       Date:  2021-07-05       Impact factor: 5.722

5.  Selected medical conditions and risk of breast cancer.

Authors:  R Talamini; S Franceschi; A Favero; E Negri; F Parazzini; C La Vecchia
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai, China) of breast cancer.

Authors:  L Lipworth; C C Hsieh; L Wide; A Ekbom; S Z Yu; G P Yu; B Xu; S Hellerstein; K Carlstrom; D Trichopoulos; H O Adami
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

7.  Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.

Authors:  Giuseppe Buono; Anna Crispo; Mario Giuliano; Carmine De Angelis; Francesco Schettini; Valeria Forestieri; Rossella Lauria; Michelino De Laurentiis; Pietro De Placido; Carmen Giusy Rea; Carmen Pacilio; Emanuela Esposito; Maria Grimaldi; Flavia Nocerino; Giuseppe Porciello; Aldo Giudice; Alfonso Amore; Anita Minopoli; Gerardo Botti; Sabino De Placido; Meghana V Trivedi; Grazia Arpino
Journal:  Breast Cancer Res Treat       Date:  2020-06-04       Impact factor: 4.872

Review 8.  The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer.

Authors:  Elizabeth O Lillie; Leslie Bernstein; Giske Ursin
Journal:  Breast Cancer Res       Date:  2003-04-02       Impact factor: 6.466

9.  Biomarkers of the metabolic syndrome and breast cancer prognosis.

Authors:  Qiu-Li Zhu; Wang-Hong Xu; Meng-Hua Tao
Journal:  Cancers (Basel)       Date:  2010-04-28       Impact factor: 6.639

10.  Adherence to the low carbohydrate diet and the risk of breast Cancer in Iran.

Authors:  Bahareh Sasanfar; Fatemeh Toorang; Ahmad Esmaillzadeh; Kazem Zendehdel
Journal:  Nutr J       Date:  2019-12-12       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.